Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversibly binding P2Y12 platelet inhibitor. It is used to reduce the rate of thrombotic cardiovascular events.
## Primary Indications
* Reduction of thrombotic cardiovascular events (including myocardial infarction and stroke) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
## Adult Dosing
* **ACS:** 180 mg orally once, followed by 90 mg orally twice daily for at least 12 months.
* **Post-MI (at least 1 year after ACS, or with high risk):** 90 mg orally twice daily.
* **Concomitant with aspirin:** Generally co-administered with aspirin 75-100 mg daily.
## Pediatric Dosing
* The use of ticagrelor in pediatric patients is not established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is required.
* **Hepatic Impairment:** No dose adjustment is required for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
## Contraindications
* Hypersensitivity to ticagrelor or any excipient.
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke (considered for patients with ACS, but discuss risk/benefit).
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (major and minor), bradycardia.
* **Serious:** Significant bleeding, hypotension, ventricular pauses.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, itraconazole) may increase ticagrelor exposure. Strong inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor exposure.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Concomitant use requires careful risk-benefit assessment.
* **Statins:** Potential for increased statin exposure (especially simvastatin, lovastatin) due to CYP3A4 inhibition.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for bradycardia.
* Evaluate therapeutic benefit and risk of bleeding, especially if switching antiplatelet therapy.
## Clinical Pearls
* Dyspnea is a common side effect and is usually mild and transient, but should be assessed to rule out other causes.
* Consider stopping ticagrelor 5 days prior to elective surgery, but balance against the risk of ischemic events.
* Ticagrelor is a reversible inhibitor, unlike clopidogrel.
***
**Disclaimer:** This information is intended for clinical use and does not replace professional medical judgment. Always consult the most current prescribing information and local protocols before making any clinical decisions.
